Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. (Q53655424)

From Wikidata

Jump to navigation Jump to search

scientific article published in October 2005

edit

Language	Label	Description	Also known as
English	Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.	scientific article published in October 2005

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

title

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

main subject

phase II clinical trial

0 references

multiple sclerosis

0 references

author

David H. Miller

series ordinal

2

object named as

David Miller

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

author name string

Paul O'Connor

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

Katherine Riester

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

Minhua Yang

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

Michael Panzara

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

Catherine Dalton

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

Katherine Miszkiel

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

Omar Khan

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

George Rice

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

William Sheremata

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

International Natalizumab Trial Group

series ordinal

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

publication date

1 October 2005

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

published in

Multiple Sclerosis Journal

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

volume

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

issue

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

page(s)

568-572

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

cites work

Integrins: a family of cell surface receptors

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

retrieved

21 January 2018

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

retrieved

21 January 2018

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

retrieved

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

retrieved

21 January 2018

A reproducible repositioning method for serial magnetic resonance imaging studies of the brain in treatment trials for multiple sclerosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

retrieved

21 January 2018

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

retrieved

21 January 2018

Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

retrieved

21 January 2018

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

retrieved

21 January 2018

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

retrieved

21 January 2018

Identifiers

DOI

10.1191/1352458505MS1205OA

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

PubMed publication ID

16193895

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16193895

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16193895

ResearchGate publication ID

7570912

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53655424&oldid=1335651909"